Ajinomoto Bio-Pharma Services Expands Fill Finish Capacity with New Multi-Purpose Fill Suite
PR89650
SAN DIEGO, May 25, 2021 /PRNewswire=KYODO JBN/ --
Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of
biopharmaceutical contract development and manufacturing services, today
announced it will soon open a high speed multi-purpose fill finish line in its
state-of-the-art commercial manufacturing facility located in San Diego, CA.
Logo - https://mma.prnewswire.com/media/751177/Aji_BioPharma_Logo.jpg
The new fill line offers a range of configurations, including prefilled
syringes, cartridges and vials, utilizing ready-to-use components, which
minimize component preparation and packaging. Along with the line, the fill
suite houses two formulation suites, one of which is capable of handling
flammable (class H) compounds.
The fully contained and integrated OPTIMA line uses SKAN isolated barrier
technology to ensure the required sterility for fill finish, while offering
flexibility to meet cGMP clinical and commercial drug product manufacturing
needs. The high-speed process is rated to move 22,000 syringes per hour through
the line, with a batch capacity of over 200 thousand syringes. In addition, it
has been designed to meet FDA and EMEA commercial compliance.
"This expansion provides a significant increase in our current aseptic
fill/finish capacity and allows for additional scheduling flexibility, as well
as component flexibility," says Paul Ruther, Director, Drug Product
Manufacturing, Ajinomoto Bio-Pharma Services. "Our continued investment in
increasing capacity further enhances Aji Bio-Pharma's commitment in being a
leading global and quality-driven CDMO with comprehensive service offerings."
The line will become fully operational in the summer 2021.
About Ajinomoto Bio-Pharma Services
Ajinomoto Bio-Pharma Services is a fully integrated contract development and
manufacturing organization with sites in Belgium, United States, Japan, and
India, providing comprehensive development, cGMP manufacturing, and aseptic
fill finish services for small and large molecule APIs and intermediates.
Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and
capabilities for pre-clinical and pilot programs to commercial quantities,
including Corynex(R) protein expression technology, oligonucleotide synthesis,
antibody drug conjugations (ADC), high potency APIs (HPAPI), biocatalysis,
continuous flow manufacturing and more. Ajinomoto Bio-Pharma Services is
dedicated to providing a high level of quality and service to meet our client's
needs. Learn more: www.AjiBio-Pharma.com
SOURCE: Ajinomoto Bio-Pharma Services
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。